Are you interested in AptarGroup, Inc.? Here are five stocks we like best.
CEO transition announced: AptarGroup CEO Stephan Tanda plans to retire on September 1, 2026, and Gael Touya, currently a director of Aptar Pharma, will take over as president and CEO. Tanda will remain as an advisor until the end of the year to help ensure a smooth transfer.
Shareholders approved all points on the ballot: At the annual meeting, investors elected four directors, approved executive compensation on an advisory basis and ratified PricewaterhouseCoopers as Aptar’s auditor for 2026. No shareholder nominations or other motions were made.
The results and outlook for 2025 were strong: Aptar reported sales growth of 5% to $3.8 billion in 2025, with Pharma leading the segment’s growth and the company returning $486 million to shareholders through buybacks and dividends. Management said first-quarter 2026 sales increased 11%, while long-term goals remain unchanged.
AptarGroup (NYSE:ATR) used its annual meeting to announce the planned CEO transition, report that shareholders approved all ballot items, and provide an update on 2025 performance and early 2026 results.
Chairman and CEO Stephan Tanda told shareholders he plans to retire after nearly 10 years in the role. Gael Touya, currently President of Aptar Pharma and a company veteran of more than 30 years, will become President and CEO on September 1, 2026.
→ The speed of light returns: Corning takes advantage of NVIDIA’s growth
Tanda said he will remain in his current role until the transition date and then serve as an advisor until the end of the year to support a smooth handover. He also said he expects to retire from the board at the end of the year, while the board hopes to appoint Touya as a director on September 1, 2026.
Touya said he was “privileged” to take on the role and thanked Tanda for his leadership, adding that Aptar has been his “professional home” for more than 30 years.
Shareholders approve directors, remuneration and auditor
→ Uber’s annual product showcase reveals what’s coming for Airbnb and Booking
Irene Hudson, executive vice president, chief legal officer and secretary, said there was a quorum at the virtual-only meeting. He said the company had not received notice of any shareholder nominations or other motions, leaving only the matters listed in the annual meeting notice for consideration.
According to preliminary vote counts, shareholders elected four directors to serve through the 2029 annual meeting: George L. Fotiades, Candace Matthews, B. Craig Owens and Julie Xing. Shareholders also approved, on an advisory basis, Aptar’s executive compensation and ratified PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm through 2026.
→ The return of Wells Fargo is real, but it is not risk-free
Tanda declared each proposal approved after the election inspector reported that the required votes had been cast in favor of the nominees and the other items on the ballot. No shareholder questions were presented during the question-and-answer portion of the meeting, according to Mary Scafidas, senior vice president of investor relations and communications.
2025 Sales increase by 5%
After the formal meeting was adjourned, Tanda reviewed the company’s business performance and recent results. He said 2025 was driven by Aptar’s purpose to “innovate and transform ideas into solutions that improve everyday life,” pointing to technologies that deliver medicines, add convenience and safety for consumers, and support recyclability, reuse and sustainability.
For 2025, reported sales increased 5% to $3.8 billion from $3.6 billion a year earlier. Core sales increased 2%, which Tanda said reflects steady demand across key product categories. The company returned $486 million to shareholders through share buybacks and dividends during the year. Tanda also noted that 2025 marked the 32nd consecutive year that Aptar paid a dividend that increases annually.
Pharma leads segment growth
Tanda highlighted the strength and diversity of the company’s pharmaceutical portfolio, citing a growing number of systemic nasal drug delivery projects and increased participation in injectable projects, including projects for GLP-1 and NX-1. The pharmaceutical segment reported 6% sales growth in 2025 to $1.74 billion, driven by strong demand for emergency medicine and central nervous system products, as well as higher royalties.
In the Beauty segment, reported sales increased 7% in 2025 to $1.31 billion, with currency and acquisitions contributing positively and core sales showing modest growth. The Closures segment reported sales growth of 2% to $730.3 million, including a foreign exchange benefit and slight growth in core sales.
Capital allocation and outlook for 2026
Tanda said Aptar has focused on investing in higher-performing, faster-growing companies, especially in the pharmaceutical sector, while remaining committed to returning capital to shareholders. Over the past five years, the company has returned $1.2 billion to shareholders through dividends and share buybacks.
For the first quarter of 2026, Tanda said reported sales increased 11%, while core sales, adjusted for foreign exchange effects and acquisitions, remained stable compared to the previous year.
It also emphasized safety, employee engagement, leadership development and community involvement. Tanda said the company’s goal of zero injuries remains a top priority and highlighted the continued expansion of Aptar Corporate University.
Aptar’s long-term financial goals remain unchanged, including an adjusted EBITDA margin target of 21% to 23% and an overall top-line sales growth target of 4% to 7%. Tanda said the company intends to continue executing a productivity roadmap aimed at addressing near-term bottlenecks and improving efficiencies across operations, supply chains and selling, general and administrative expenses.
“In closing, 2025 was a strong year and we are well positioned for broad-based growth across all three of our segments,” Tanda said. He added that Aptar’s balance sheet provides the company with the ability to invest for the future, return capital to shareholders and maintain flexibility for strategic opportunities.
About AptarGroup (NYSE:ATR)
AptarGroup, Inc is a global provider of advanced dispensing, sealing and protection solutions for the pharmaceutical and consumer markets. The company designs and manufactures a broad portfolio of products that enable the controlled delivery of liquids, gels, powders and aerosols. Its customer base spans the beauty and personal care, home care, food and beverage and pharmaceutical sectors, where innovation in packaging and medication delivery devices drives brand differentiation and regulatory compliance.
In consumer markets, AptarGroup offers specialized pumps, actuators, valves, closures and bottles designed for precision, convenience and sustainability.
This instant news alert was generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest reporting and unbiased coverage. Send any questions or comments about this story to contact@marketbeat.com.
The article “AptarGroup Sets CEO Succession as Sales Surge in 2025 and Shareholders Back Vote” was originally published by MarketBeat.
